中国中药公告集团附属公司国药集团同济堂（贵州）制药有限公司的1.1类中药创新药郁枢达片注册上市申请已获国家药品监督管理局受理。郁枢达片具有醒脾化湿、理气解郁的功效临床研究证实其对气机郁滞所致的情绪郁闷、低落等症状有显著疗效尤其在改善抑郁障碍早期轻型、中型症状方面表现出色。同济堂制药于2024年完成的III期临床试验结果显示郁枢达片在治疗轻、中度抑郁症时展现出良好的安全性和有效性且疗效显著优于安慰剂组。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.